What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.

This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.

US22RYB00924_Rybelsus MOA & Dosing Enduring Video.mp4